This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

This study has been completed.
Information provided by (Responsible Party):
Synta Pharmaceuticals Corp. Identifier:
First received: March 6, 2009
Last updated: September 17, 2014
Last verified: September 2014
The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies.

Condition Intervention Phase
AML CML MDS Myeloproliferative Disorders Drug: STA-9090 (ganetespib) Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice Weekly in Subjects With Hematologic Malignancies

Resource links provided by NLM:

Further study details as provided by Synta Pharmaceuticals Corp.:

Primary Outcome Measures:
  • To characterize the safety and tolerability of STA-9090 (ganetespib) in subjects with hematologic malignancies [ Time Frame: Feb 2011 ]
  • To assess preliminary evidence of anti-neoplastic activity [ Time Frame: Feb 2011 ]
  • To assess the pharmacokinetics of STA-9090 (ganetespib) when administered as a short-term intravenous infusion [ Time Frame: Feb 2011 ]

Secondary Outcome Measures:
  • To assess changes in biomarkers following study drug administration [ Time Frame: Feb 2011 ]
  • To investigate drug exposure levels/plasma concentrations and correlations with efficacy and safety parameters [ Time Frame: Feb 2011 ]
  • To assess the impact of variations in drug metabolizing enzymes (DME pharmacogenomics) on the pharmacokinetics of STA-9090 (ganetespib) [ Time Frame: Feb 2011 ]

Enrollment: 31
Study Start Date: March 2009
Study Completion Date: February 2013
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort Drug: STA-9090 (ganetespib)
Chemotherapy agent


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Males and females 18 years or older
  • Eligible subjects must have one of the following relapsed or refractory hematologic malignancies: AML, MDS, CML, or myeloproliferative disorders as defined in the protocol
  • Must have acceptable organ function during screening as defined in the protocol

Exclusion Criteria

  • Pregnant or breast-feeding women
  • Patients must meet the washout periods for prior chemotherapies and radiation
  • History of stroke within 6 months of treatment
  • Poor venous access for study drug administration
  • Treatment with chronic immunosuppressants
  • Other severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00858572

United States, Massachusetts
Boston, Massachusetts, United States, 02115
United States, New York
New York, New York, United States, 10065
United States, Texas
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Synta Pharmaceuticals Corp.
  More Information

Responsible Party: Synta Pharmaceuticals Corp. Identifier: NCT00858572     History of Changes
Other Study ID Numbers: 9090-03
Study First Received: March 6, 2009
Last Updated: September 17, 2014

Keywords provided by Synta Pharmaceuticals Corp.:
myeloproliferative disorder
hematologic malignancy

Additional relevant MeSH terms:
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases processed this record on August 17, 2017